NEW YORK (GenomeWeb News) – Bruker reported today that its revenues in the third quarter were down 2 percent year over year, falling to $439 million from $447.8 million in Q3 2012.

The drop was driven by weakness in the company's Energy and Semiconducting Technologies (BEST) segment, which saw revenue decline by 27 percent in the quarter. Bruker's Scientific Instruments segment, which includes its mass spectrometry and life sciences business, grew a fraction of 1 percent year over year.

The results fell short of the average Wall Street estimate of $452.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.